Modality
Bispecific Ab
MOA
TNFi
Target
SMN2
Pathway
Wnt
Melanoma
Development Pipeline
Preclinical
~Dec 2023
→ ~Mar 2025
Phase 1
Jun 2025
→ Nov 2029
Phase 1Current
NCT06481137
2,852 pts·Melanoma
2025-07→TBD·Active
NCT07781681
1,724 pts·Melanoma
2025-06→2029-11·Recruiting
4,576 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-243.7y awayInterim· Melanoma
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Recruit…
P1
Active
Catalysts
Interim
2029-11-24 · 3.7y away
Melanoma
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06481137 | Phase 1 | Melanoma | Active | 2852 | Safety |
| NCT07781681 | Phase 1 | Melanoma | Recruiting | 1724 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |